CIC and Amadeus lead £3.25m round for Riverlane

Cambridge Enterprise also took part in the round, which will enable the company to develop its product for a number of quantum computing hardware platforms, and expand its team of software researchers and computational physicists.

Amadeus is currently investing from Amadeus IV Early Stage, which has a £50m target and invests in sectors including medical technology and digital healthcare.

Company
Founded in 2017 by University of Cambridge senior research fellow Steve Brierley, Riverlane develops a simulation platform for drug and material discovery. The product accounts for quantum effects and is designed to reduce the need for expensive laboratory testing. Its algorithms can be used for applications including drug–protein interactions, biomolecule folding and materials science.

People
Cambridge Innovation Capital – Andrew Williamson (managing partner).
Amadeus Capital Partners – Amelia Armour (principal).
Riverlane – Steve Brierley (founder, CEO).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Expansion
• UK / Ireland
• Technology
• United Kingdom
• Amadeus Capital
• Venture